Picard Medical Q1 preliminary revenue up 79.9% to $1.1M; driven by STAH sales

Picard Medical, Inc.

Preliminary unaudited revenue of $1.1M for Q1 2026 vs $0.6M in Q1 2025, a 79.9% increase.
Growth driven by higher SynCardia Total Artificial Heart (STAH) sales, favorable U.S. reimbursement, and pricing adjustments on driver rentals.
CEO cites progress in commercial initiatives and increased STAH utilization as bridge-to-transplant.
Full Q1 results to be filed in Form 10-Q on or before May 15, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Picard Medical, Inc. reported first quarter ended March 31, 2026 results: revenue $1.1 million.

Period: first quarter ended March 31, 2026
Revenue: $1.1 million
Result: preliminary results

Exact text from the filing

Revenue rose 79.9% to $1.1 million for the three months ended March 31, 2026, from $0.6 million for the three months ended March 31, 2025

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Picard Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-26-003733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.